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 Meijer  et al. 1 (this issue) report a positive 
cross-sectional association between 
plasma copeptin and microalbuminuria 
within the population sample of the Pre-
vention of Renal and Vascular End-Stage 
Disease (PREVEND) Study, which 
includes adults both with and without 
kidney dysfunction. Copeptin is the 
C-terminal part of the vasopressin pro-
hormone and is secreted stoichiometri-
cally with vasopressin. Th us it is used as 
a marker of endogenous vasopressin 
secretion and has been used by studies in 
various clinical areas, such as infectious 
diseases and cardiovascular diseases. 2,3 
 Th e data of Meijer  et al. show that the 
prevalence of urinary albumin excretion 
of at least 30  mg per 24  hours is approxi-
mately two times higher in individuals 
with plasma copeptin in the upper quin-
tile of the distribution than in individuals 
with plasma copeptin in the lowest quin-
tile, among either men or women. 1 Th e 
direct association of plasma copeptin with 
urinary albumin excretion was, at least in 
part, statistically independent of several 
factors, including age and blood pressure 
status. Data about volume and osmolarity 
in 24-hour urine supported the view that 
plasma copeptin was inversely related to 
the level of hydration, as expected for a 
marker of endogenous vasopressin secre-
tion. 4 Th e association of plasma copeptin 
with high urinary albumin excretion was 
not explained by high glomerular fi ltra-
tion rate (GFR), because individuals with 
high plasma copeptin actually had higher 
serum creatinine and lower estimated 
GFR in comparison with individuals with 
low plasma copeptin. Th us, the data alto-
gether indicated that the high urinary 
albumin excretion of individuals with 
high plasma copeptin reasonably refl ected 
an increase in the permeability of the 
glomerular fi lter to plasma albumin and /
 or a decrease in the albumin reabsorption 
at the tubular level. Th e authors conclude 
that, in addition to its well-known anti-
diuretic eff ect in the renal collecting ducts, 
vasopressin might also exert  per se an intra-
renal pro-albuminuric effect.  Figure 1 
summarizes the classical relationships of 
vasopressin with kidney function and the 
hypothesis proposed by Meijer  et al. 1 
 Th e few available interventional studies 
on vasopressin and urinary albumin sup-
port the interpretation of Meijer  et al. 1 Th e 
group of Bankir and co-workers analyzed 
the eff ects of the administration of a vaso-
pressin analog in rats and in small series of 
healthy individuals or patients with diabe-
tes insipidus. 5 – 7 Th ey reported an increase 
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 Copeptin is a marker of endogenous vasopressin secretion. Population-
based data of the PREVEND Study show that men and women with high 
plasma copeptin have a highly prevalent microalbuminuria in addition to 
the low level of hydration typical of persons with high vasopressin secretion. 
The association of plasma copeptin with microalbuminuria suggests that 
vasopressin might have a role in kidney dysfunction via effects on the 
permselectivity of the glomerulus and / or on tubular albumin reabsorption. 
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in urinary albumin excretion together with 
the expected increase in urinary concentra-
tion. However, a substantial contrast arises 
when one compares the results of the PRE-
VEND Study with the past observations of 
Bankir and co-workers about the relation 
between vasopressin and GFR. In fact, data 
of the PREVEND Study suggest a negative 
eff ect of vasopressin on GFR (the higher 
the plasma copeptin, the lower the esti-
mated GFR), whereas Bankir and co-work-
ers reported a GFR increase after 
vasopressin administration in acute- or 
short-term-intervention studies. 6 – 8 Inulin 
clearance studies in healthy humans are in 
accordance with the observations of Bankir 
and co-workers, because GFR decreased in 
the presence of an acute increase in the 
level of hydration, hence in the presence of 
conditions that are able to suppress vaso-
pressin secretion. 8 A possible explanation 
of these inconsistencies is that the results of 
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 Figure 1  |  Classical relationship of 
vasopressin with kidney function, and 
hypothesis proposed by Meijer  et al. 1 
GFR, glomerular filtration rate. 
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acute or short-term interventions could be 
not always representative of the  ‘ free-living ’ 
conditions typical of population-based 
studies such as the PREVEND Study. An 
alternative possibility is that some of the 
associations of copeptin with other varia-
bles refl ected the infl uence of determinants 
of vasopressin secretion rather than the 
eff ects of vasopressin  per se . For instance, 
data of the PREVEND Study indicated that 
the correlation coeffi   cient of plasma copep-
tin with urinary sodium  per se (a marker of 
salt intake) was substantially similar to the 
correlation coeffi  cient of plasma copeptin 
with overall urine osmolarity calculated on 
the basis of the urinary concentrations of 
sodium and other osmolytes. 1 
 Meijer  et al. 1 did not investigate the pos-
sible role of dietary determinants of plasma 
copeptin, because they did not include uri-
nary sodium and other osmolytes in the set 
of multivariate regression analyses. Th us, it 
is impossible to exclude that, at least in some 
individuals, a higher level of vasopressin 
secretion (that is, a higher level of plasma 
copeptin) was secondary to dietary habits 
characterized by high salt intake. In turn, the 
higher salt intake could be responsible for an 
elevation in vasopressin secretion via changes 
in plasma osmolarity on one hand, and in 
urinary albumin excretion on the other 
hand, as found in the Framingham Off spring 
Study. 9 Th e hypothetical pro-albuminuric 
eff ect of high salt intake could be mediated 
by an increase in glomerular pressure and / or 
a decrease in tubular reabsorption. 10 Th e role 
of inherited factors in this complex interplay 
is not defi ned but is proved by the observa-
tion that, within the population sample of 
the PREVEND Study, men had much higher 
levels of plasma copeptin and of urinary 
albumin excretion than women. 
 In conclusion, the observational study by 
Meijer  et al. 1 opens up a new frontier in the 
research area focusing on prevention and 
control of renal disease. Th e new set of data 
from the PREVEND Study supports the 
idea of a multifactorial regulation of urinary 
albumin excretion and puts forward the 
intriguing possibility that vasopressin 
should be added to the mosaic of the deter-
minants of microalbuminuria. Th is hypoth-
esis needs to be further investigated and 
confi rmed, but it is in keeping also with 
some data from intervention studies about 
the eff ects of the short-term administration 
of vasopressin analogs. Th e possible pro-
albuminuric role of vasopressin could also 
be investigated by interventional studies 
aiming to block the secretion of endogenous 
vasopressin or the effects of circulating 
vasopressin. At present, dietary interven-
tions consisting of an increased water intake 
or a decreased osmolyte intake appear as 
the only practical tools to reduce the secre-
tion of endo genous vasopressin. Th e use of 
vasopressin receptor antagonists represents 
hopefully a future option in the investiga-
tion of the blockade of vasopressin eff ects. 
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of prospective trials 
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 Diagnosis and treatment of atherosclerotic renal artery stenosis (ARAS) in 
the elderly is a never-ending challenge for every nephrologist. Kalra  et al. 
report that adjusted hazard ratios for ARAS increased threefold from 
1992 to 2004 in 16 million United States Renal Data System participants 
aged 66 years or older. However, numbers of revascularizations showed a 
biphasic pattern with a declining number since 1999. These exciting data 
have to be discussed with the knowledge of recent prospective trials. 
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 Th e signifi cance of atherosclerotic renal 
artery stenosis (ARAS) for the clinical 
outcome of patients with hypertension 
and / or chronic kidney disease is still a 
matter of debate between nephro logists, 
interventional cardiologists, and radio-
logists. 1 There is no doubt about the 
increasing number of renal artery inter-
ventions over the past two decades in the 
United States as well as in Europe; how-
ever, the benefi t of these interventions 
remains a mystery. 2 Meanwhile, stenting 
of ARAS has been the treatment of choice 
